Listen
OCTAGAM 50 mg/ml (human immunoglobulin)
NEUROLOGY - New indication
Opinions on drugs -
Posted on
Mar 23 2015
Reason for request
Extension of indication
No clinical benefit demonstrated by comparison with TEGELINE and PRIVIGEN in chronic inflammatory demyelinating polyradiculoneuropathy
-
OCTAGAM, human immunoglobulin for intravenous administration, now has Marketing Authorisation in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
-
There was no proven clinical advantage compared with TEGELINE and PRIVIGEN. Its role in the therapeutic strategy is similar to that of these other immunoglobulins.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
